Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Drug Developed in U.K. to Treat Solid Tumors

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
Cancer Research U.K.'s Drug Development Office; Cancer Research Technology, and Lorus Therapeutics Inc. have partnered to take a new therapy with the potential to treat solid tumors into its first clinical trial.

The treatment, IL-17E, is a type of protein called a pro-inflammatory cytokine which, according to research done at Lorus, is thought to elicit an immune response which attacks cancer cells, and determining exactly how it does this will form part of the work being done. It incorporates technology owned by both Lorus and Genentech, after Lorus scientists discovered the anticancer properties of IL-17E against a range of solid tumors.

Cancer Research U.K.'s Clinical Development Partnerships (CDP) is a joint initiative between Cancer Research UK's Drug Development Office (DDO) and Cancer Research Technology. The partnership seeks to develop promising anticancer agents that may not otherwise be developed, and take them through preclinical development and early clinical trials.

With the CDP scheme, companies retain the background rights to their programs while enabling Cancer Research U.K. to take on early development work to evaluate the benefit to cancer patients. Three drugs are now in clinical trials with others scheduled to open in early 2013.

Cancer Research U.K.'s DDO will fund and undertake extensive preclinical work led by Professor Christian Ottensmeier at the University of Southampton, England, to further investigate the mechanism by which the protein destroys cancer cells and to further develop the drug for use in treating cancer patients.

The DDO will then fund, manage, and sponsor the first Phase I clinical trial led by Professor Chris Twelves and Dr. Christy Ralph at the Cancer Research U.K./NIHR Leeds Experimental Cancer Medicine Centre, based at the University of Leeds, England. Lorus will manufacture and supply IL-17E for the non-clinical toxicology and Phase I clinical studies.

After the Phase I trial, Lorus will have the exclusive option to license the Phase I clinical trial data and resume further clinical development. If it does not exercise this option, the rights to the program would be transferred to Cancer Research Technology to secure an alternative partner, with the aim to make the treatment available for cancer patients while Lorus would retain certain economic interests.

IL-17E was selected following a rigorous peer-review process conducted by Cancer Research U.K.'s New Agents Committee (NAC). Assessment of IL-17E by the NAC was based on several criteria, including scientific rationale, quality of the anticancer data in relevant tumor models, novelty, and clinical need. IL-17E is the eighth treatment to enter Cancer Research U.K.'s Clinical Development Partnerships scheme.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Tuesday, August 04, 2015
‘Liquid Biopsies’ Could Help Spot Genetic Faults in Lung Cancer
Study analyze blood samples from 97 patients who took part in the EURTAC clinical trial.
Saturday, March 07, 2015
New Companies Join Cancer Research UK Consortium
Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia.
Thursday, December 11, 2014
Why Bowel Cancer Sometimes Outsmarts Treatment
New study challenges the prevailing view of how bowel cancer develops in the large intestine.
Tuesday, December 02, 2014
CRUK and AstraZeneca Collaborate
Cancer Research UK to collaborate with AstraZeneca in screening for new cancer medicines at the AstraZeneca MRC UK Centre for Lead Discovery.
Friday, November 28, 2014
Cancer Cell Fingerprints in the Blood May Speed up Childhood Cancer Diagnosis
Researchers found unique molecular fingerprints for 11 types of children’s tumours, to develop blood tests to diagnose these cancers.
Tuesday, November 04, 2014
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner
Partnership Developed to Trial Immunotherapy Vaccine For Lung Cancer
Friday, September 12, 2014
Cancer Research UK, Astellas Partner on Cancer Treatments
The new collaboration will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.
Friday, August 08, 2014
New Route to Boost Pancreatic Cancer Treatment
Cancer Research UK scientists have uncovered new insights into how the key pancreatic cancer drug gemcitabine is broken down in tumour cells.
Monday, June 02, 2014
Cancer Research UK, AZ and Pfizer Partner to Advance Lung Cancer Treatment
Partnership creates a pioneering clinical trial for patients with advanced lung cancer, marking a new era of research into personalised medicines to treat cancer.
Thursday, April 17, 2014
DNA Sequencing Reveals Mucosal Melanoma's Bullseye
Scientists have found a molecular 'bullseye' for a rare form of melanoma, opening up opportunities for new targeted treatment.
Wednesday, June 12, 2013
Final Results from the Phase III TeloVac Trial in Pancreatic Cancer
Results from the trial showed no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy.
Tuesday, June 04, 2013
Astronomy Algorithms Help Diagnose Aggressive Tumors
Scientists have honed techniques originally developed to spot distant galaxies and used them to identify biomarkers that signal a cancer’s aggressiveness among some 2,000 breast tumours.
Monday, February 25, 2013
Study Points to Potential New Treatment for Deadly Pancreatic Cancer
Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.
Tuesday, May 01, 2012
Scientists Find New Drug Target for Hard-to-Treat Leukaemia
Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival.
Friday, March 30, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!